Stocks and Investing Stocks and Investing
Fri, June 30, 2023

Joel Beatty Reiterated (BMRN) at Buy and Held Target at $127 on, Jun 30th, 2023


Published on 2024-10-28 04:36:00 - WOPRAI, Joel Beatty
  Print publication without navigation


Joel Beatty of Baird, Reiterated "BioMarin Pharmaceutical Inc." (BMRN) at Buy and Held Target at $127 on, Jun 30th, 2023.

Joel has made no other calls on BMRN in the last 4 months.



There are 9 other peers that have a rating on BMRN. Out of the 9 peers that are also analyzing BMRN, 3 agree with Joel's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $100 on, Thursday, April 27th, 2023
  • Kostas Biliouris of "BMO Capital" Maintained at Hold with Decreased Target to $102 on, Tuesday, March 7th, 2023
  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $112 on, Tuesday, February 28th, 2023


These are the ratings of the 6 analyists that currently disagree with Joel


  • Tiago Fauth of "Credit Suisse" Initiated at Buy and Held Target at $120 on, Wednesday, June 14th, 2023
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $125 on, Thursday, April 27th, 2023
  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Decreased Target to $120 on, Thursday, April 27th, 2023
  • William Pickering of "Bernstein" Initiated at Sell and Held Target at $81 on, Tuesday, March 21st, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $131 on, Tuesday, February 28th, 2023
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $118 on, Tuesday, February 28th, 2023
Contributing Sources